Seth Ettenberg Net Worth

The estimated Net Worth of Seth Ettenberg is at least $27 mil dollars as of 25 March 2019. Seth Ettenberg owns over 11,485 units of Unum Therapeutics stock worth over $26,990 and over the last 6 years Seth sold UMRX stock worth over $0.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Seth Ettenberg UMRX stock SEC Form 4 insiders trading

Seth has made over 6 trades of the Unum Therapeutics stock since 2018, according to the Form 4 filled with the SEC. Most recently Seth exercised 11,485 units of UMRX stock worth $2,067 on 25 March 2019.

The largest trade Seth's ever made was exercising 11,485 units of Unum Therapeutics stock on 25 March 2019 worth over $2,067. On average, Seth trades about 7,657 units every 20 days since 2018. As of 25 March 2019 Seth still owns at least 11,485 units of Unum Therapeutics stock.

You can see the complete history of Seth Ettenberg stock trades at the bottom of the page.

What's Seth Ettenberg's mailing address?

Seth's mailing address filed with the SEC is C/O UNUM THERAPEUTICS INC., 200 CAMBRIDGE PARK DRIVE, SUITE 3100, CAMBRIDGE, MA, 02140.

Insiders trading at Unum Therapeutics

Over the last 7 years, insiders at Unum Therapeutics have traded over $0 worth of Unum Therapeutics stock and bought 1,283,156 units worth $11,122,392 . The most active insiders traders include Llc Fmr, Liam Ratcliffe, eBruce Booth. On average, Unum Therapeutics executives and independent directors trade stock every 72 days with the average trade being worth of $286,216. The most recent stock trade was executed by Healthcare Capital Partners... on 14 August 2020, trading 451,000 units of UMRX stock currently worth $1,136,520.

What does Unum Therapeutics do?

Unum Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel immunotherapy products designed to harness the power of a patient’s immune system to cure cancer. The firm’s technologies include Antibody-Coupled T-cell Receptor, which is a chimeric protein that binds to tumor targeting antibodies. The company was founded by Charles Wilson and Dario Campana in March 2014 and is headquartered in Cambridge, MA.

Complete history of Seth Ettenberg stock trades at Unum Therapeutics

Unum Therapeutics executives and stock owners

Unum Therapeutics executives and other stock owners filed with the SEC include:

• Karen Ferrante,
  Independent Director
• Arlene Morris,
  Independent Director
• Matthew Ros,
  Independent Director
• Stephanie Ascher,
  Investor Relations
• Peter Harwin,
  Director
• Chris Cain,
  Director
• Jessica Sachs,
  Chief Medical Officer
• John Green,
  Chief Financial Officer, Vice President - Finance, Controller
• Andrew Robbins,
  President, Chief Executive Officer and Principal Executive Officer, Director
• Llc Fmr,
  
• Bruce Booth,
  Director
• Funds Management Llc Fairmount,
  10% owner
• Ltd Fil,
  
• Venture Fund Ix, L.P.Atlas ...,
  
• Liam Ratcliffe,
  Director
• Jorn Aldag,
  Director
• Robert J Perez,
  Director
• Seth Ettenberg,
  Chief Scientific Officer
• Geoffrey Hodge,
  Chief Technical Officer
• Charles Wilson,
  Chief Executive Officer
• Michael Vasconcelles,
  Chief Medical Officer
• Matthew Scott Osborne,
  Chief Financial Officer
• Healthcare Capital Partners...,